December 22, 2014 11:56 PM ET

Pharmaceuticals

Company Overview of Icon Bioscience, Inc.

Company Overview

Icon Bioscience, Inc. operates as a specialty biopharmaceutical company focusing on the development and commercialization of ophthalmic pharmaceuticals in the United States. The company’s products include IBI-10090, a biodegradable therapeutic for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery; IBI-20089, an injectable intraocular sustained release product for the delivery of triamcinolone acetonide; IBI-60089, a biodegradable product for the delivery of therapeutic levels of latanoprost to the anterior chamber; and IBI-80090 (mephalan for intraocular injection) for the treatment of retinoblastoma. It also develops products to trea...

1253 Reamwood Avenue

Sunnyvale, CA 94089

United States

Founded in 2004

Phone:

650-369-4049

Key Executives for Icon Bioscience, Inc.

Chief Executive Officer and President
Age: 50
Founder and Chairman
Age: 82
Vice President of Finance & Administration
Vice President of Clinical Development
Manufacturing & Operations Advisor
Compensation as of Fiscal Year 2014.

Icon Bioscience, Inc. Key Developments

Icon Bioscience, Inc. Completes Treatment in its Pivotal Phase 3 Study of IBI-10090

Icon Bioscience, Inc. announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. Top-line data is expected to be reported in the fourth quarter of 2014. Employing Icon's Verisome technology, IBI-10090 is designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.

Icon Bioscience Announces Early Completion of Patient Enrollment in its Phase 3 Study of IBI-10090

Icon Bioscience, Inc. announced the completion of patient enrollment in its pivotal phase 3 study of IBI-10090, approximately four months ahead of projected timelines. IBI-10090, which employs the Verisome technology, is Icon's lead pipeline product. It has been designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery. With some three million cataract surgeries performed annually in the US alone, IBI-10090 addresses a potentially large market. Moreover, the current standard of care for inflammation associated with cataract surgery involves a comparatively burdensome process of patient administered eye drops applied topically several times daily over an extended time period.

David S. Tierney Joins Icon Bioscience, Inc. as President & Chief Executive Officer

Icon Bioscience, Inc. announced that David S. Tierney, MD joined the company as President & Chief Executive Officer. Previously, Dr. Tierney served as President & COO of Oceana Therapeutics, Inc., a company he co-founded in mid-2008.

Similar Private Companies By Industry

Company Name Region
Bactolac Pharmaceutical Inc. United States
SphingoGene, Inc. United States
PNC Labs, Inc. United States
Sanofi-Synthelabo Inc. United States
Variant Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Icon Bioscience, Inc., please visit www.iconbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.